GLTO Quote, Financials, Valuation and Earnings

Evaxion Biotech AS has a net margin of -- compared to Galecto's net margin of -64.14%. Galecto's return on equity of -- beat Evaxion Biotech AS's return on equity of --.

Galecto has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1192.23%. Given that Evaxion Biotech AS has higher upside potential than Galecto, analysts believe Evaxion Biotech AS is more attractive than Galecto.

Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Galecto quarterly revenues are --, which are smaller than Evaxion Biotech AS quarterly revenues of $3M. Galecto's net income of -$3.9M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Galecto's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 1.24x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab AS has a net margin of -- compared to Galecto's net margin of 22.85%. Galecto's return on equity of -- beat Genmab AS's return on equity of 14.86%.

Galecto has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand Genmab AS has an analysts' consensus of $36.56 which suggests that it could grow by 78.58%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.991%.

Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

Galecto quarterly revenues are --, which are smaller than Genmab AS quarterly revenues of $816.4M. Galecto's net income of -$3.9M is lower than Genmab AS's net income of $186.6M. Notably, Galecto's price-to-earnings ratio is -- while Genmab AS's PE ratio is 19.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 4.62x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

IO Biotech has a net margin of -- compared to Galecto's net margin of --. Galecto's return on equity of -- beat IO Biotech's return on equity of --.

Galecto has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand IO Biotech has an analysts' consensus of -- which suggests that it could grow by 889.01%. Given that IO Biotech has higher upside potential than Galecto, analysts believe IO Biotech is more attractive than Galecto.

Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

Galecto quarterly revenues are --, which are smaller than IO Biotech quarterly revenues of --. Galecto's net income of -$3.9M is higher than IO Biotech's net income of -$24M. Notably, Galecto's price-to-earnings ratio is -- while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -- compared to Galecto's net margin of 38.28%. Galecto's return on equity of -- beat Novo Nordisk AS's return on equity of 88.95%.

Galecto has a consensus price target of --, signalling upside risk potential of 105.76%. On the other hand Novo Nordisk AS has an analysts' consensus of $122.21 which suggests that it could grow by 39.88%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.66% to investors and pays a quarterly dividend of $0.52 per share. Galecto pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galecto quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Galecto's net income of -$3.9M is lower than Novo Nordisk AS's net income of $4B. Notably, Galecto's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 28.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 9.92x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.